By Senator Harrell

25-01462-21 20211392

A bill to be entitled

An act relating to health insurance coverage for cancer treatment; amending s. 627.4239, F.S.; defining the terms "associated condition" and "health care provider"; prohibiting health maintenance organizations from excluding coverage for certain cancer treatment drugs; prohibiting health insurers and health maintenance organizations from requiring, before providing prescription drug coverage for the treatment of stage 4 metastatic cancer and associated conditions, that treatment has failed with a different drug; providing applicability; prohibiting insurers and health maintenance organizations from excluding coverage for certain drugs on certain grounds; prohibiting insurers and health maintenance organizations from requiring that certain cancer treatment drugs be sent to certain entities for home infusion unless a certain condition is met; revising construction; providing an effective date.

2021

1

2

3

4

5

6

7

8

9

10

11

12

13

1415

16

17

18

19

Be It Enacted by the Legislature of the State of Florida:

2223

24

Section 1. Section 627.4239, Florida Statutes, is amended to read:

25

627.4239 Coverage for use of drugs in treatment of cancer.-

2627

(1) DEFINITIONS.—As used in this section, the term:(a) "Associated condition" means a symptom or side effect

2829

that:

1. Is associated with a particular cancer at a particular

25-01462-21 20211392

stage or with the treatment of that cancer; and

2. In the judgment of a health care provider, will further jeopardize the health of a patient if left untreated. As used in this subparagraph, the term "health care provider" means a physician licensed under chapter 458, chapter 459, or chapter 461, a physician assistant licensed under chapter 458 or chapter 459, an advanced practice registered nurse licensed under chapter 466.

- (b) "Medical literature" means scientific studies published in a United States peer-reviewed national professional journal.
- (c) (b) "Standard reference compendium" means authoritative compendia identified by the Secretary of the United States

 Department of Health and Human Services and recognized by the federal Centers for Medicare and Medicaid Services.
 - (2) COVERAGE FOR TREATMENT OF CANCER.
- (a) An insurer or a health maintenance organization may not exclude coverage in any individual or group health insurance policy or health maintenance contract issued, amended, delivered, or renewed in this state which covers the treatment of cancer for any drug prescribed for the treatment of cancer on the ground that the drug is not approved by the United States Food and Drug Administration for a particular indication, if that drug is recognized for treatment of that indication in a standard reference compendium or recommended in the medical literature.
- (b) Coverage for a drug required by this section also includes the medically necessary services associated with the administration of the drug.
 - (3) COVERAGE FOR TREATMENT OF STAGE 4 METASTATIC CANCER AND

25-01462-21 20211392

ASSOCIATED CONDITIONS.-

(a) An insurer or a health maintenance organization may not require in any individual or group health insurance policy or health maintenance contract issued, amended, delivered, or renewed in this state which covers the treatment of stage 4 metastatic cancer and its associated conditions that, before a drug prescribed for the treatment is covered, the insured or subscriber fail or have previously failed to respond successfully to a different drug.

- (b) Paragraph (a) applies to a drug that is recognized for the treatment of such stage 4 metastatic cancer or its associated conditions, as applicable, in a standard reference compendium or that is recommended in the medical literature. The insurer or health maintenance organization may not exclude coverage for such drug on the ground that the drug is not approved by the United States Food and Drug Administration for such stage 4 metastatic cancer or its associated conditions, as applicable.
- (4) COVERAGE FOR SERVICES ASSOCIATED WITH DRUG ADMINISTRATION.—Coverage for a drug required by this section also includes the medically necessary services associated with the administration of the drug.
- (5) PROHIBITION ON MANDATORY HOME INFUSION.—An insurer or a health maintenance organization may not require that a cancer medication be administered using home infusion, and may not require that such medication be sent directly to a third party or to the patient for home infusion unless the patient's treating oncologist determines that home infusion of the cancer medication will not jeopardize the health of the patient.

25-01462-21 20211392

(6)(3) APPLICABILITY AND SCOPE.—This section may not be construed to:

- (a) Alter any other law with regard to provisions limiting coverage for drugs that are not approved by the United States Food and Drug Administration, except for drugs for the treatment of stage 4 metastatic cancer or its associated conditions.
- (b) Require coverage for any drug, except for a drug for the treatment of stage 4 metastatic cancer or its associated conditions, if the United States Food and Drug Administration has determined that the use of the drug is contraindicated.
- (c) Require coverage for a drug that is not otherwise approved for any indication by the United States Food and Drug Administration, except for a drug for the treatment of stage 4 metastatic cancer or its associated conditions.
- (d) Affect the determination as to whether particular levels, dosages, or usage of a medication associated with bone marrow transplant procedures are covered under an individual or group health insurance policy or health maintenance organization contract.
 - (e) Apply to specified disease or supplemental policies.
- <u>(f)</u> (4) Nothing in this section is intended, Expressly or by implication, to create, impair, alter, limit, modify, enlarge, abrogate, prohibit, or withdraw any authority to provide reimbursement for drugs used in the treatment of any other disease or condition.
 - Section 2. This act shall take effect January 1, 2022.